[1]吴文钰,李斐斐,CHUNG Shuetling(马来西亚),等.中西医治疗乳腺癌术后他莫昔芬相关子宫内膜病变研究进展[J].陕西中医,2023,(12):1831-封3.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.037]
　WU Wenyu,LI Feifei,CHUNG Shuetling,et al.Research progress on treatment of tamoxifen-associated endometrial lesions after breast cancer surgery by integrative medicine[J].,2023,(12):1831-封3.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.037]
点击复制

中西医治疗乳腺癌术后他莫昔芬相关子宫内膜病变研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年12期
页码:
1831-封3
栏目:
综 述
出版日期:
2023-12-05

文章信息/Info

Title:
Research progress on treatment of tamoxifen-associated endometrial lesions after breast cancer surgery by integrative medicine
作者:
吴文钰1; 李斐斐1; CHUNG Shuetling(马来西亚)2; 刘 胜1
(1.上海中医药大学附属龙华医院,上海 200030; 2.上海中医药大学附属第七人民医院,上海 200137)
Author(s):
WU Wenyu; LI Feifei; CHUNG Shuetling; LIU Sheng
(Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200030,China)
关键词:
乳腺癌;  子宫内膜病变;  他莫昔芬;  癥瘕;  雌激素;  辨证论治
Keywords:
Breast cancer;  Endometrial lesion;  Tamoxifen;  Zhengjia;  Estrogen;  Differentiation and treatment
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7369.2023.12.037
文献标志码:
A
摘要:
他莫昔芬是乳腺癌治疗的一线药物,长期口服他莫昔芬可引起子宫内膜增厚、子宫内膜息肉,甚至有子宫内膜癌变的风险,影响患者生存。目前,他莫昔芬相关子宫内膜病变的机制尚不完全清楚。西医认为与他莫昔芬在子宫内膜组织中的弱雌激素作用有关。中医秉持整体与局部辨证的统一观念,认为本病发生的基础在于“正气亏虚”,发展的关键在于肝脾肾三脏功能失调,疾病形成的核心在于“瘀血”内积于胞宫,应辨为“癥瘕”论治,以行气消癥或补益肝肾为大法治疗,可以显著缓解病情,改善症状,提升生活质量。
Abstract:
Tamoxifen is the first line drug in the treatment of breast cancer.Long-term oral tamoxifen can cause endometrial thickening,endometrial polyps,and even increase the risk of endometrial cancer,which will reduces survival of breast cancer patients.At present,the pathogenesis of tamoxifen-related endometrial lesions is not completely clear.Western medicine believes that is related to the weak estrogen effect of tamoxifen in endometrial tissue.Traditional Chinese medicine upholds the unified concept of holistic and local syndrome differentiation.The basis of tamoxifen-related endometrial lesions is the deficiency of positive qi,the key to development is the dysfunction of the liver,spleen and kidney,and the core of the disease is the accumulation of blood stasis,which should be treated from the perspective of “Zhengjia”,and the treatment should be based on either promoting qi and eliminating blood,or tonifying the liver and kidney,which can significantly relive the disease and symptoms,improve the quality of life for patients.

参考文献/References:

[1] Nilsson S,Koehler KF.Oestrogen receptors and selective oestrogen receptor modulators:Molecular and cellular pharmacology[J].Basic Clin Pharmacol Toxicol,2005,96(1):15-25.
[2] Davies C,Pan H,Godwin J,et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J].Lancet,2013,381(9869):805-816.
[3] 尹树山,陶 艳,张红英.雌、孕激素受体在晚期局部乳腺癌中的表达及与患者预后相关性研究[J].陕西医学杂志,2019,48(12):1718-1721.
[4] Ryu KJ,Kim MS,Lee JY,et al.Risk of endometrial polyps,hyperplasia,carcinoma,and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer[J].JAMA Netw Open,2022,5(11):e2243951.
[5] Choi S,Lee YJ,Jeong JH,et al.Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen:A nationwide study[J].Front Oncol,2021,11:636378.
[6] Jung H,Jung JK,Kim SB,et al.Comparative study on hysteroscopic and histologic examinations of the endometrium in postmenopausal women taking tamoxifen[J].J Menopausal Med,2018,24(2):81-86.
[7] Ghanavati M,Khorshidi Y,Shadnoush M,et al.Tamoxifen use and risk of endometrial cancer in breast cancer patients:A systematic review and dose-response meta-analysis[J].Cancer Rep(Hoboken),2023,6(4):e1806.
[8] Hu R,Hilakivi-Clarke L,Clarke R.Molecular mechanisms of tamoxifen-associated endometrial cancer[J].Oncol Lett,2015,9(4):1495-1501.
[9] 蔡翩翩.宫腔镜检查在诊断他莫昔芬相关子宫内膜病变中的作用[D].天津:天津医科大学,2018.
[10] 蔡利平.经阴道彩超、磁共振成像及宫腔镜对子宫内膜癌病理分期的诊断价值[J].黑龙江医学,2021,45(23):2540-2541.
[11] 贺永艳,薛 雪,王晓林,等.左炔诺孕酮宫内节育系统与乳腺癌的相关性研究进展[J].实用妇产科杂志,2020,36(9):676-679.
[12] Philip S,Taylor AH,Konje JC,et al.The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen[J].Obstet Gynaecol,2019,39(8):1117-1122.
[13] 邹妮倩,许青青,赵新月,等.宫内放置曼月乐对乳腺癌术后服用他莫昔芬患者子宫内膜的影响及安全性的Meta分析[J].广西医学,2022,44(3):325-330,337.
[14] 王 丽,朱红英,张群昌.宫腔镜联合曼月乐手术治疗子宫内膜息肉疗效观察[J].陕西医学杂志,2019,48(7):920-922.
[15] Chu SC,Hsieh CJ,Wang TF,et al.Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use:A population-based study in Taiwan[J].Ci Ji Yi Xue Za Zhi,2019,32(2):175-180.
[16] 王 伟,陈 旭,王 平.GnRh对乳腺癌根治术后口服他莫昔芬患者子宫内膜的保护研究[J].中国肿瘤临床与康复,2019,26(6):645-648.
[17] Davis SR,Robinson PJ,Jane F,et al.The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial[J].Clin Endocrinol,2018,89(5):605-612.
[18] 杨秋莉,王学芬,张向农.古代中医对乳腺癌的认识[J].中国中医基础医学杂志,2010,16(5):437-439.
[19] 陈玮黎,薛晓红,李思雨,等.扶正祛邪方对三阴性乳腺癌术后复发转移及免疫功能的影响[J].陕西中医,2021,42(6):739-742.
[20] 刘双文.温阳益气方对乳腺癌术后内分泌治疗患者生活质量影响的临床研究[D].北京:北京中医药大学,2016.
[21] 迟皓南.加味二仙汤对乳腺癌术后内分泌治疗期类更年期综合征的疗效及机制研究[D].济南:山东中医药大学,2022.
[22] 师 宇.基于患者需求的乳腺癌术后内分泌治疗伴随症状中医证型分布规律及相关影响因素研究[D].天津:天津中医药大学,2022.
[23] 贺晓立,王 军,余 静,等.沈力教授治疗乳腺癌十一法[J].陕西中医,2020,41(1):92-94.
[24] 刘 静.陆德铭治疗乳癌术后放化疗及内分泌治疗中不良反应的经验撷萃[J].环球中医药,2016,9(3):327-329.
[25] 武晓媛.慈菇平岩方对他莫昔芬治疗乳腺癌所致肝郁脾虚型子宫内膜增厚的疗效观察[D].张家口:河北北方学院,2021.
[26] 夏婷婷.桂枝茯苓丸加减对他莫昔芬治疗相关子宫内膜增厚的影响[D].济南:山东中医药大学,2022.
[27] 王旺胜,尤建良,薛 青,等.益肾沉潜方联合他莫昔芬对乳腺癌患者子宫内膜厚度及体力状况的影响[J].山西中医,2020,36(3):30-32.
[28] 盛 文.加味地黄汤治疗他莫昔芬所致子宫内膜增生的临床研究[D].昆明:云南中医药大学,2014.

相似文献/References:

[1]陈 楠,王光辉△,贺 赛,等.养正合剂改善乳腺癌术后化疗者不适及对患者细胞因子、红细胞免疫的影响[J].陕西中医,2019,(10):1357.
　CHEN Nan,WANG Guanghui,HE Sai,et al.Yangzheng mixture improves the discomfort of postoperative chemotherapy in patients with breast cancer and its immunity to cytokines and red blood cells[J].,2019,(12):1357.
[2]张贺,姜大庆.鸦胆子素D对乳腺癌MDAMB231细胞增殖与凋亡及细胞周期的影响*[J].陕西中医,2019,(11):1495.
　ZHANG He,JIANG Daqing..Effects of Bruceine D on proliferation,apoptosis and cell cycle of breast cancer MDAMB231 cells[J].,2019,(12):1495.
[3]张栓宝,张燕平△,严宁娟.康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响[J].陕西中医,2019,(11):1566.
　ZHANG Shuanbao,ZHANG Yanping,YAN Ningjuan..Effect of Kanglaite injection on immune function,VEGF and quality of life in patients with breast cancer receiving neoadjuvant chemotherapy[J].,2019,(12):1566.
[4]贺晓立,王 军,余 静,等.沈力教授治疗乳腺癌十一法*[J].陕西中医,2020,(1):92.
　HE Xiaoli,WANG Jun,YU Jing,et al.Professor SHEN Li’s treatment of breast cancer by using eleven TCM methods[J].,2020,(12):92.
[5]刘歆春,李锁南,黄飞燕.乳岩汤联合西药治疗乳腺癌疗效及对患者免疫功能的影响[J].陕西中医,2021,(9):1201.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.012]
[6]冯秀梅,马 兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,(11):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
　FENG Xiumei,MA Lan,LUO Yuqun,et al.Yiqi Huoxue recipe to inhibit breast cancer cell proliferation and invasion and increase the expression of miR-100[J].,2021,(12):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
[7]陈 军,孙 嫘,惠建荣,等.艾灸对三阴性乳腺癌移植瘤小鼠生存期的影响及机制研究[J].陕西中医,2022,(7):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
　CHEN Jun,SUN Lei,HUI Jianrong,et al.Effect and mechanism of moxibustion on survival of triple negative breast cancer transplanted tumor mice[J].,2022,(12):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
[8]陈明明,郭 旭,熊乙霓,等.培元固本法治疗乳腺癌化疗后骨髓抑制临床研究[J].陕西中医,2022,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.014]
[9]蔡丽珍,白瑞娜,张 路,等.基于“痰夹瘀血”理论探讨乳腺癌相关淋巴水肿因机治疗[J].陕西中医,2023,(10):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
　CAI Lizhen,BAI Ruina,ZHANG Lu,et al.Based on the theory of “phlegm blended with blood stasis”,to explore the mechanism and treatment of breast cancer related lymphedema[J].,2023,(12):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
[10]宋铁兵,李康乐,马 强,等.土贝母皂苷甲对乳腺癌细胞MCF-7凋亡的影响[J].陕西中医,2023,(11):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]
　SONG Tiebing,LI Kangle,MA Qiang,et al.Effect of Tubeimoside I on apoptosis of breast cancer cell MCF-7[J].,2023,(12):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助面上项目(81774308)
更新日期/Last Update: 2023-12-08